Hospital General Universitario Santa Lucía, Cartagena, Murcia, España.
Hospital General Universitario Santa Lucía, Cartagena, Murcia, España.
Med Clin (Barc). 2018 Jan 23;150(2):61-63. doi: 10.1016/j.medcli.2017.06.021. Epub 2017 Jul 23.
There are a lot of venous thromboembolism risk assessment models with the aim of predicting the individual risk of venous thromboembolism (VTE), although most have not been externally validated. The objective of our study was to analyse the concordance among the Padua, PRETEMED, IMPROVE and MEDENOX scores.
Observational cohort study with 602 patients admitted to Medical Services of the Hospital Universitario Santa Lucía. Concordance was calculated using the kappa index (KI) between the four risk prediction scales and the VTE occurring within 90 days of hospitalisation.
Patients considered were those with a high risk of VTE, 78%, 56%, 69% and 59% according to Padua, PRETEMED, IMPROVE and MEDENOX scores respectively. A KI=0.60 was observed among Padua-IMPROVE scores; KI=0.44 among IMPROVE-PRETEMED, KI=0.43 among PRETEMED-MEDENOX, KI=0.33 among Padua-PRETEMED, KI=0.27 among IMPROVE-MEDENOX and a KI=0.24 among Padua-MEDENOX. During follow-up, nine cases of VTE (1.5%) were observed.
The highest degree of agreement was observed among the Padua and IMPROVE scores. There is no good agreement between any of the predictive risk scales for VTE in medical patients. The Padua score was the best predictor of VTE episodes at 90 days among high risk patients.
有许多静脉血栓栓塞风险评估模型旨在预测个体静脉血栓栓塞(VTE)的风险,尽管大多数模型尚未经过外部验证。我们的研究目的是分析 Padua、PRETEMED、IMPROVE 和 MEDENOX 评分之间的一致性。
这是一项观察性队列研究,纳入了 602 名入住 Hospital Universitario Santa Lucía 医疗服务的患者。使用四个风险预测量表与住院后 90 天内发生的 VTE 之间的 Kappa 指数(KI)来计算一致性。
根据 Padua、PRETEMED、IMPROVE 和 MEDENOX 评分,患者分别被认为具有高、中、高和中高度 VTE 风险,占比分别为 78%、56%、69%和 59%。Padua-IMPROVE 评分之间的 KI 值为 0.60;IMPROVE-PRETEMED 之间为 0.44;PRETEMED-MEDENOX 之间为 0.43;Padua-PRETEMED 之间为 0.33;IMPROVE-MEDENOX 之间为 0.27;Padua-MEDENOX 之间为 0.24。在随访期间,观察到 9 例 VTE(1.5%)。
Padua 和 IMPROVE 评分之间的一致性最高。在预测医疗患者 VTE 的风险量表中,没有任何一种量表之间具有良好的一致性。在高危患者中,Padua 评分是预测 90 天内 VTE 发作的最佳指标。